The brain galanin receptors: targets for novel antidepressant drugs. 2007

Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
Molecular and Integrative Neuroscience Department (MIND) and The Harold L. Dorris Neurological Research Center, The Scripps Research Institute, 10550 North Torrey Pines Rd (SR-307), La Jolla, CA 92037, USA.

Our present view that the mood disorders involve dysfunction of monoaminergic system is a result of important clinical and preclinical observations over the past 40 years. The therapeutic efficacy of drugs such as the tricyclic antidepressants (TCAs), monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs) and lately of SNRIs (serotonin and norepinephrine reuptake inhibitors) helped to shape our view that mood regulation involves the monoaminergic systems in some way. It is thus little surprising when the neuropeptide, galanin, is discovered to coexist with norepinephrine (NE) in locus coeruleus (LC) neurons and with serotonin (5-HT) in the dorsal raphe nucleus (DRN) neurons, a link between galanin mediated signaling and mood regulation is sought. Galanin receptors are expressed in brain structures that are involved in the regulation of mood such as frontal cortex, amygdala, hypothalamus, LC, DRN and hippocampus. It is almost an accident of research fate that the potent effects of galanin on cognitive performance and seizure threshold have led galanin research to focus on the hippocampus where the neuropeptide is present in cholinergic and noradrenergic afferents and where the receptor density is much lower than in the monoaminergic nuclei. Hopefully it is not too late to report on the recent inroads into the roles of galanin and of galanin receptor subtypes 2 and 3 (GalR2 and GalR3) in mood regulation in animal models as well as in human patients with major depression. A body of existing data suggests that GalR2 signaling leads to antidepressant-like, anticonvulsant and neurogenesis-promoting effects, a spectrum of activities that are commonly associated with efficacious antidepressants. Similarly, GalR3 antagonists exhibit anxiolytic and antidepressant-like activity, another clinically useful combination for the treatment of mood disorders. Since both GalR2 and GalR3 are G-protein coupled receptors (GPCRs), a favorite target class for drug development, we believe that the pace of developing galaninergic antidepressants will increase significantly from now on.

UI MeSH Term Description Entries
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant
D044088 Receptors, Galanin A family of G-protein-coupled receptors that are specific for GALANIN and galanin peptides. They are generally considered to be coupled to the GI, INHIBITORY G-PROTEIN to meditate the neurological effects of galanin. Several subtypes of galanin receptors occur with differing specificities for the full length galanin, galanin peptide fragments, and galanin-like peptide. Galanin Receptor,Galanin Receptors,Receptor, Galanin
D019004 Galanin A neuropeptide of 29-30 amino acids depending on the species. Galanin is widely distributed throughout the BRAIN; SPINAL CORD; and INTESTINES. There are various subtypes of GALANIN RECEPTORS implicating roles of galanin in regulating FOOD INTAKE; pain perception; memory; and other neuroendocrine functions. Galanin (1-29),Galanin (1-30)

Related Publications

Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
March 1978, Nature,
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
November 2003, Journal of psychiatry & neuroscience : JPN,
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
January 2010, Experientia supplementum (2012),
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
June 2008, Cellular and molecular life sciences : CMLS,
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
February 2023, CNS spectrums,
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
January 2006, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry,
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
May 2015, Neurogastroenterology and motility,
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
September 2021, Pharmaceuticals (Basel, Switzerland),
Xiaoying Lu, and Lisa Sharkey, and Tamas Bartfai
December 2008, Current psychiatry reports,
Copied contents to your clipboard!